Synthesis and in vitro evaluation of novel liver X receptor agonists based on naphthoquinone derivatives

Tatsuma Nishioka, Kaori Endo-Umeda, Yuki Ito, Akane Shimoda, Atsuko Takeuchi, Chisato Tode, Yoshihisa Hirota, Naomi Osakabe, Makoto Makishima, Yoshitomo Suhara

Research output: Contribution to journalArticle

Abstract

We aimed to synthesize novel liver X receptor (LXR) agonists with potent agonist activity and subtype selectivity. Our synthetic scheme started with naphthoquinone derivatives, such as menadione and 2,3-dichloro-1,4-naphthoquinone. We introduced different substituents into the naphthoquinone structures, including aniline, piperidine, pyrrolidine, and morpholine, in one or two steps, and thus, we produced 14 target compounds. All 14 synthetic ligands were tested to determine whether they mediated LXR-mediated transcriptional activity. We investigated the transcriptional activity of each compound with two types of receptors, LXRα and LXRβ. Among all 14 compounds, two showed weak LXRβ-agonist activity, and two others exhibited potent LXRα-agonist activity. We also performed docking studies to obtain a better understanding of the modes of compound binding to LXR at the atomic level. In conclusion, we successfully synthesized naphthoquinone derivatives that act as LXRα/β agonists and selective LXRα agonists.

Original languageEnglish
Article number4316
JournalMolecules
Volume24
Issue number23
DOIs
Publication statusPublished - 2019 Nov 26

Fingerprint

Naphthoquinones
liver
Liver
Derivatives
evaluation
synthesis
Vitamin K 3
piperidine
aniline
selectivity
Ligands

Keywords

  • Agonist
  • Liver X receptor (LXR)
  • Naphthoquinone
  • Transcriptional activity
  • α-selective

ASJC Scopus subject areas

  • Analytical Chemistry
  • Chemistry (miscellaneous)
  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery
  • Physical and Theoretical Chemistry
  • Organic Chemistry

Cite this

Synthesis and in vitro evaluation of novel liver X receptor agonists based on naphthoquinone derivatives. / Nishioka, Tatsuma; Endo-Umeda, Kaori; Ito, Yuki; Shimoda, Akane; Takeuchi, Atsuko; Tode, Chisato; Hirota, Yoshihisa; Osakabe, Naomi; Makishima, Makoto; Suhara, Yoshitomo.

In: Molecules, Vol. 24, No. 23, 4316, 26.11.2019.

Research output: Contribution to journalArticle

Nishioka, Tatsuma ; Endo-Umeda, Kaori ; Ito, Yuki ; Shimoda, Akane ; Takeuchi, Atsuko ; Tode, Chisato ; Hirota, Yoshihisa ; Osakabe, Naomi ; Makishima, Makoto ; Suhara, Yoshitomo. / Synthesis and in vitro evaluation of novel liver X receptor agonists based on naphthoquinone derivatives. In: Molecules. 2019 ; Vol. 24, No. 23.
@article{a8617dab90914c34afe2f9910c34b757,
title = "Synthesis and in vitro evaluation of novel liver X receptor agonists based on naphthoquinone derivatives",
abstract = "We aimed to synthesize novel liver X receptor (LXR) agonists with potent agonist activity and subtype selectivity. Our synthetic scheme started with naphthoquinone derivatives, such as menadione and 2,3-dichloro-1,4-naphthoquinone. We introduced different substituents into the naphthoquinone structures, including aniline, piperidine, pyrrolidine, and morpholine, in one or two steps, and thus, we produced 14 target compounds. All 14 synthetic ligands were tested to determine whether they mediated LXR-mediated transcriptional activity. We investigated the transcriptional activity of each compound with two types of receptors, LXRα and LXRβ. Among all 14 compounds, two showed weak LXRβ-agonist activity, and two others exhibited potent LXRα-agonist activity. We also performed docking studies to obtain a better understanding of the modes of compound binding to LXR at the atomic level. In conclusion, we successfully synthesized naphthoquinone derivatives that act as LXRα/β agonists and selective LXRα agonists.",
keywords = "Agonist, Liver X receptor (LXR), Naphthoquinone, Transcriptional activity, α-selective",
author = "Tatsuma Nishioka and Kaori Endo-Umeda and Yuki Ito and Akane Shimoda and Atsuko Takeuchi and Chisato Tode and Yoshihisa Hirota and Naomi Osakabe and Makoto Makishima and Yoshitomo Suhara",
year = "2019",
month = "11",
day = "26",
doi = "10.3390/molecules24234316",
language = "English",
volume = "24",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "23",

}

TY - JOUR

T1 - Synthesis and in vitro evaluation of novel liver X receptor agonists based on naphthoquinone derivatives

AU - Nishioka, Tatsuma

AU - Endo-Umeda, Kaori

AU - Ito, Yuki

AU - Shimoda, Akane

AU - Takeuchi, Atsuko

AU - Tode, Chisato

AU - Hirota, Yoshihisa

AU - Osakabe, Naomi

AU - Makishima, Makoto

AU - Suhara, Yoshitomo

PY - 2019/11/26

Y1 - 2019/11/26

N2 - We aimed to synthesize novel liver X receptor (LXR) agonists with potent agonist activity and subtype selectivity. Our synthetic scheme started with naphthoquinone derivatives, such as menadione and 2,3-dichloro-1,4-naphthoquinone. We introduced different substituents into the naphthoquinone structures, including aniline, piperidine, pyrrolidine, and morpholine, in one or two steps, and thus, we produced 14 target compounds. All 14 synthetic ligands were tested to determine whether they mediated LXR-mediated transcriptional activity. We investigated the transcriptional activity of each compound with two types of receptors, LXRα and LXRβ. Among all 14 compounds, two showed weak LXRβ-agonist activity, and two others exhibited potent LXRα-agonist activity. We also performed docking studies to obtain a better understanding of the modes of compound binding to LXR at the atomic level. In conclusion, we successfully synthesized naphthoquinone derivatives that act as LXRα/β agonists and selective LXRα agonists.

AB - We aimed to synthesize novel liver X receptor (LXR) agonists with potent agonist activity and subtype selectivity. Our synthetic scheme started with naphthoquinone derivatives, such as menadione and 2,3-dichloro-1,4-naphthoquinone. We introduced different substituents into the naphthoquinone structures, including aniline, piperidine, pyrrolidine, and morpholine, in one or two steps, and thus, we produced 14 target compounds. All 14 synthetic ligands were tested to determine whether they mediated LXR-mediated transcriptional activity. We investigated the transcriptional activity of each compound with two types of receptors, LXRα and LXRβ. Among all 14 compounds, two showed weak LXRβ-agonist activity, and two others exhibited potent LXRα-agonist activity. We also performed docking studies to obtain a better understanding of the modes of compound binding to LXR at the atomic level. In conclusion, we successfully synthesized naphthoquinone derivatives that act as LXRα/β agonists and selective LXRα agonists.

KW - Agonist

KW - Liver X receptor (LXR)

KW - Naphthoquinone

KW - Transcriptional activity

KW - α-selective

UR - http://www.scopus.com/inward/record.url?scp=85075775418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075775418&partnerID=8YFLogxK

U2 - 10.3390/molecules24234316

DO - 10.3390/molecules24234316

M3 - Article

C2 - 31779181

AN - SCOPUS:85075775418

VL - 24

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 23

M1 - 4316

ER -